BTIG Downgrades Protagonist Therapeutics(PTGX.US) to Hold Rating, Raises Target Price to $67
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics Price Target Raised to $67 From $51 at BTIG
Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
